Literature DB >> 31473906

The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia.

Chutima Roomruangwong1, Cristiano Noto2,3, Buranee Kanchanatawan1, George Anderson4, Marta Kubera5, Andre F Carvalho6,7, Michael Maes8,9,10.   

Abstract

Several lines of evidence indicate that aberrations in immune-inflammatory pathways may contribute to the pathophysiology of schizophrenia spectrum disorders. Here, we propose a novel theoretical framework that was previously developed for major depression and bipolar disorder, namely, the compensatory immune-regulatory reflex system (CIRS), as applied to the neuro-immune pathophysiology of schizophrenia and its phenotypes, including first-episode psychosis (FEP), acute relapses, chronic and treatment-resistant schizophrenia (TRS), comorbid depression, and deficit schizophrenia. These schizophrenia phenotypes and manifestations are accompanied by increased production of positive acute-phase proteins, including haptoglobin and α2-macroglobulin, complement factors, and macrophagic M1 (IL-1β, IL-6, and TNF-α), T helper (Th)-1 (interferon-γ and IL-2R), Th-2 (IL-4, IL-5), Th-17 (IL-17), and T regulatory (Treg; IL-10 and transforming growth factor (TGF)-β1) cytokines, cytokine-induced activation of the tryptophan catabolite (TRYCAT) pathway, and chemokines, including CCL-11 (eotaxin), CCL-2, CCL-3, and CXCL-8. While the immune profiles in the different schizophrenia phenotypes indicate the activation of the immune-inflammatory response system (IRS), there are simultaneous signs of CIRS activation, including increased levels of the IL-1 receptor antagonist (sIL-1RA), sIL-2R and tumor necrosis factor-α receptors, Th-2 and Treg phenotypes with increased IL-4 and IL-10 production, and increased levels of TRYCATs and haptoglobin, α2-macroglobulin, and other acute-phase reactants, which have immune-regulatory and anti-inflammatory effects. Signs of activated IRS and CIRS pathways are also detected in TRS, chronic, and deficit schizophrenia, indicating that these conditions are accompanied by a new homeostatic setpoint between upregulated IRS and CIRS components. In FEP, increased baseline CIRS activity is a protective factor that may predict favorable clinical outcomes. Moreover, impairments in the CIRS are associated with deficit schizophrenia and greater impairments in semantic and episodic memory. It is concluded that CIRS plays a key role in the pathophysiology of schizophrenia by negatively regulating the primary IRS and contributing to recovery from the acute phase of illness. Therefore, components of the CIRS may offer promising therapeutic targets for schizophrenia.

Entities:  

Keywords:  CIRS; Cytokines; Immune regulatory; Immune system; Immunology; Inflammation; Psychiatry; Psychosis; Schizophrenia

Year:  2019        PMID: 31473906     DOI: 10.1007/s12035-019-01737-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  28 in total

1.  The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments.

Authors:  Abbas F Almulla; Asara Vasupanrajit; Chavit Tunvirachaisakul; Hussein K Al-Hakeim; Marco Solmi; Robert Verkerk; Michael Maes
Journal:  Mol Psychiatry       Date:  2022-04-14       Impact factor: 15.992

2.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

3.  Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.

Authors:  Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Amer Alhaideri; Michael Maes
Journal:  Metab Brain Dis       Date:  2020-09-23       Impact factor: 3.584

4.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

5.  In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy.

Authors:  Hussein Kadhem Al-Hakeim; Rana Fadhil Mousa; Arafat Hussein Al-Dujaili; Michael Maes
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

6.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

Review 7.  Biomarkers for Deep Brain Stimulation in Animal Models of Depression.

Authors:  Jason Yuen; Aaron E Rusheen; Joshua Blair Price; Abhijeet S Barath; Hojin Shin; Abbas Z Kouzani; Michael Berk; Charles D Blaha; Kendall H Lee; Yoonbae Oh
Journal:  Neuromodulation       Date:  2021-06-09

8.  Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients.

Authors:  Paolo Enrico; Giuseppe Delvecchio; Nunzio Turtulici; Alessandro Pigoni; Filippo Maria Villa; Cinzia Perlini; Maria Gloria Rossetti; Marcella Bellani; Antonio Lasalvia; Chiara Bonetto; Paolo Scocco; Armando D'Agostino; Stefano Torresani; Massimiliano Imbesi; Francesca Bellini; Angela Veronese; Luisella Bocchio-Chiavetto; Massimo Gennarelli; Matteo Balestrieri; Gualtiero I Colombo; Annamaria Finardi; Mirella Ruggeri; Roberto Furlan; Paolo Brambilla
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 9.306

9.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.

Authors:  Michael Maes; Aristo Vojdani; Sunee Sirivichayakul; Decio S Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

10.  False Dogmas in Schizophrenia Research: Toward the Reification of Pathway Phenotypes and Pathway Classes.

Authors:  Michael Maes; George Anderson
Journal:  Front Psychiatry       Date:  2021-06-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.